Corneal transplantation preventing transplant rejection
This research was completed on 30 September 2004
|Project Leader||Dr Andrew J T George MA PhD MRCPath and Mr Daniel F P Larkin MD|
|Location||Department of Immunology, Hammersmith Hospital in conjunction with Moorfields Eye Hospital, London.|
|Grant awarded||26 October 2000|
|Start date||1 October 2001|
|End date||30 September 2004|
We do not provide medical advice. If you would like more information about a condition or would like to talk to someone about your health, contact NHS Choices or speak to your GP. Please see our useful links page for some links to health information, organisations we are working with and other useful organisations. We hope you will find these useful. We are not responsible for the content of any of these sites.
Corneal grafting is the most common form of transplantation and a major way of treating and reversing blindness, with 60-80,000 operations performed worldwide each year. About a quarter of all these grafts fail within 5 years, and in some groups of patients (such as children or those with eye infections) the majority are rapidly rejected. This team is working to prevent such corneal rejection by using molecules which are normally used by viruses to protect themselves from the immune system. (The molecules confuse the immune system and prevent it from attacking the virus.) The aim of this study is to cause the corneas to make these particular molecules, in order to similarly confuse the immune system and thereby stop it from attacking the graft.